Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Mult Scler ; 28(7): 1146-1150, 2022 06.
Article in English | MEDLINE | ID: covidwho-1861996


Monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) received emergency use authorization for the acute treatment of COVID-19. We are not aware of published data on their use in immunosuppressed people with multiple sclerosis (pwMS). We report 23 pwMS (mean age = 49 years, ocrelizumab (n = 19), fingolimod (n = 2), vaccinated with at least an initial series (n = 19)) who received mAb for acute COVID-19. Following mAb receipt, approximately half recovered in <7 days (48%). There were no adverse events or deaths. Use of mAb for pwMS treated with fingolimod or ocrelizumab was not observed to be harmful and is likely helpful for treatment of acute COVID-19.

COVID-19 , Multiple Sclerosis , Antibodies, Viral , Fingolimod Hydrochloride/therapeutic use , Humans , Middle Aged , Multiple Sclerosis/chemically induced , Multiple Sclerosis/complications , Multiple Sclerosis/drug therapy , SARS-CoV-2
Brain Behav Immun ; 89: 601-603, 2020 10.
Article in English | MEDLINE | ID: covidwho-651618


We describe a man whose first manifestations of Creutzfeldt-Jakob disease occurred in tandem with symptomatic onset of coronavirus disease 2019 (COVID-19). Drawing from recent data on prion disease pathogenesis and immune responses to SARS-CoV-2, we hypothesize that the cascade of systemic inflammatory mediators in response to the virus accelerated the pathogenesis of our patient's prion disease. This hypothesis introduces the potential relationship between immune responses to the novel coronavirus and the hastening of preclinical or manifest neurodegenerative disorders. The global prevalence of both COVID-19 and neurodegenerative disorders adds urgency to the study of this potential relationship.

Brain/diagnostic imaging , Coronavirus Infections/complications , Creutzfeldt-Jakob Syndrome/complications , Pneumonia, Viral/complications , Aged , Betacoronavirus , Brain/physiopathology , COVID-19 , Coronavirus Infections/immunology , Creutzfeldt-Jakob Syndrome/diagnosis , Creutzfeldt-Jakob Syndrome/immunology , Creutzfeldt-Jakob Syndrome/physiopathology , Disease Progression , Electroencephalography , Fluorodeoxyglucose F18 , Humans , Magnetic Resonance Imaging , Male , Pandemics , Pneumonia, Viral/immunology , Positron-Emission Tomography , Radiopharmaceuticals , SARS-CoV-2